AXSM vs MASI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 3/9, indicating significant operational and profitability concerns. Despite strong revenue growth of 63.2% and a bullish analyst recommendation, the company is deeply unprofitable with a -40.89% profit margin, negative ROE of -275.50%, and a high debt/equity ratio of 2.96. Valuation metrics are stretched, with a forward P/E of 423x and a price-to-book of 126.85, while insider selling of $85.54M in the last six months signals strong bearish sentiment from management. Although the stock has delivered impressive price performance over the past year (+79%), these gains appear disconnected from fundamentals, increasing vulnerability to downside correction.
MASI exhibits a severe valuation disconnect, trading at $178.47 despite a Graham Number of $34.54 and an Intrinsic Value of $26.81. While the Piotroski F-Score of 4/9 indicates stable financial health, the company is struggling with a negative profit margin (-9.92%) and a concerning Q/Q revenue collapse of -31.33%. Strong gross margins and ROE are offset by a significant YoY EPS decline of -31.7% and bearish insider sentiment. The stock is currently priced for perfection in a deteriorating short-term growth environment.
Compare Another Pair
Related Comparisons
AXSM vs MASI: Head-to-Head Comparison
This page compares Axsome Therapeutics, Inc. (AXSM) and Masimo Corporation (MASI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.